<DOC>
	<DOCNO>NCT00511459</DOCNO>
	<brief_summary>This phase 2 , randomize , placebo control , multi-center study estimate treatment effect evaluate safety tolerability AMG 386 combination paclitaxel paclitaxel/bevacizumab treatment subject Her2-negative metastatic locally recurrent breast cancer . AMG 386 man-made medication design stop development blood vessel cancer tissue . Cancer tissue rely development new blood vessel , process call angiogenesis , obtain supply oxygen nutrient grow .</brief_summary>
	<brief_title>Phase 2 Study AMG 386 Plus Paclitaxel With Without Bevacizumab First Line Therapy Her2-Negative Breast Cancer Patients</brief_title>
	<detailed_description>Primary Objective : To estimate treatment effect measure progression free survival ( PFS ) subject receive AMG 386 ( 2 dos ) combination paclitaxel + bevacizumab relative paclitaxel + bevacizumab + placebo . Secondary Objective ( ) : - To compare treatment effect measure PFS subject receive open-label AMG 386 combination paclitaxel relative paclitaxel + bevacizumab + placebo - To compare treatment effect measure PFS subject receive AMG 386 combination paclitaxel bevacizumab relative paclitaxel + AMG 386 - To evaluate safety tolerability combination non-bevacizumab regimens - To estimate measure ( RR , DOR , TTR , TTP ) treatment effect - To evaluate pharmacokinetics ( PK ) AMG 386 bevacizumab use combination - To estimate incidence anti-AMG386 antibody formation Exploratory Objective ( ) : - To explore pharmacodynamic ( PD ) response assess change blood level angiogenic cytokine , tumor apoptosis , marker - To explore association histological feature select immunologic , biochemical , pharmacogenetic , angiogenic marker tumor biopsy , plasma , serum sample safety and/or efficacy outcome Study Design : This phase 2 , randomize , placebo control , multi-center study estimate treatment effect evaluate safety tolerability AMG 386 combination paclitaxel paclitaxel/bevacizumab treatment subject Her2-negative metastatic locally recurrent breast cancer . Two hundred twenty subject randomize 1:1:1:1 follow arm : Arm A : Paclitaxel 90 mg/m² IV QW ( 3 on/1 ) + bevacizumab 10 mg/kg IV Q2W + AMG 386 10 mg/kg IV QW Arm B : Paclitaxel 90 mg/m² IV QW ( 3 on/1 ) + bevacizumab 10 mg/kg IV Q2W + AMG 386 3 mg/kg IV QW Arm C : Paclitaxel 90 mg/m² IV QW ( 3 on/1 ) + bevacizumab 10 mg/kg IV Q2W + AMG 386 placebo IV QW Arm D : Paclitaxel 90 mg/m² IV QW ( 3 on/1 ) + Open Label AMG 386 10 mg/kg IV QW To maintain double-blind arm A , B , C , subject infused weekly volume investigational product equivalent 10 mg/kg AMG 386 IV . Arm D receive open label AMG 386 receive placebo bevacizumab . Subjects discontinue study treatment time radiographic disease progression , clinical progression , unacceptable toxicity , subject withdrawal consent , death . Subjects alive time discontinuation study medication follow 48 month date last subject enrol trial evaluate overall survival . Radiological image assess disease status perform every 8 week ± 7 day ( 2 cycle ) 2 year every 4 month ± 1 month thereafter study subject develop radiographic disease progression per modify RECIST criterion . In addition , subject discontinues study drug treatment prior disease progression continue radiological imaging perform every 8 week ± 7 day long term follow period subject study 2 year subject develop radiographic disease progression begin new treatment . If subject study 2 year , radiological imaging every 4 month ± 1 month perform long term follow-up period subject develop radiographic disease progression begin new treatment . The overall study design describe study schema immediately follow synopsis . Amgen Global Safety ( AGS ) charter data review team ( DRT ) independent team conduct study review unblinded safety data 20 , 40 , 80 subject randomize opportunity receive least 1 cycle ( 4 week ) study treatment .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Trebananib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Subjects must histologically cytologically confirm adenocarcinoma breast locally recurrent metastatic disease . Locally recurrent disease must amenable resection curative intent . Measurable nonmeasurable disease per modify RECIST guideline ECOG 0 1 ( within 14 day prior randomization ) Adequate organ hematological function evidence follow laboratory study within 14 day prior randomization : • Cardiac function , follow : Normal sinus rhythm ( significant ECG change ) Left ventricular ejection fraction ≥ LLN , determine echocardiogram MUGA scan , accord institutional standard within 28 day prior randomization Inflammatory Breast Cancer Common Terminology Criteria Adverse Events ( CTCAE ) Version 3.0 peripheral neuropathy &gt; grade 1 randomization History arterial venous thrombosis , include transient ischemic attack ( TIA ) , within 1 year prior randomization Adjuvant neoadjuvant taxane treatment within 12 month randomization . Any adjuvant chemotherapy regimen must discontinue least 21 day prior randomization Prior chemotherapy , vaccine , biological therapy locally recurrent metastatic breast cancer ( prior endocrine therapy permit ) Prior radiation therapy , radiofrequency ablation , percutaneous cryotherapy hepatic chemoembolization sit disease unless disease progression subsequently document 14 day prior randomization . Overexpression HER2 ( gene amplification FISH 3+ expression immunohistochemistry ) . Current prior history central nervous system metastasis History bleed diathesis clinically significant bleeding within 6 month prior randomization Major surgical procedure within 28 day prior randomization Open breast biopsy within 14 day prior randomization Minor surgical procedure , placement access device , fine needle aspiration within 7 day first dose Prior malignancy ( thyroid cancer , situ cervical cancer , basal cell cancer skin , treat curative intent without evidence disease ≥ 3 year prior randomization ) Clinically significant cardiac disease within 12 month prior randomization , include myocardial infarction , unstable angina , grade 2 great peripheral vascular disease , cerebrovascular accident , transient ischemic attack , congestive heart failure , arrhythmia control outpatient medication Nonhealing wound , ulcer fracture Known hypersensitivity paclitaxel drug use vehicle cremophor Known hypersensitivity bacterial protein , drug require study Known positive test human immunodeficiency virus ( HIV ) , hepatitis C , hepatitis B surface antigen Known active chronic hepatitis Uncontrolled hypertension define systolic blood pressure ≥ 150 mm Hg diastolic blood pressure ≥ 90 mm Hg . Antihypertensive medication allow subject stable current dose time randomization Currently previously treat VEGF VEGFr inhibitor , include limited , bevacizumab , SU11248 ( sunitinib ) , PTK787 ( vatalinib ) , AZD 2171 , AEE788 , BAY 439006 ( sorafenib ) AMG 706 . Treatment coumarintype anticoagulant , ( low dose prophylaxis central venous catheter ≤ 1mg/day ) within 7 day prior randomization Currently previously treat angiopoietin inhibitor , inhibitor TIE1 TIE2 include , limited , AMG 386 , XL880 , XL820 Treatment immune modulators cyclosporine tacrolimus within 30 day prior randomization Concomitant therapy hormonal agent raloxifene , tamoxifen , selective estrogen receptor modulators ( SERMS ) , give breast cancer prevention osteoporosis . Subjects must discontinue agent 28 day prior randomization Pregnant ( ie , positive betahuman chorionic gonadotropin test ) breast feeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Randomized</keyword>
	<keyword>4-Arm</keyword>
	<keyword>Placebo control</keyword>
	<keyword>Phase 2 Trial</keyword>
	<keyword>AMG 386</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>First-line Therapy</keyword>
	<keyword>Her-2 Negative</keyword>
	<keyword>Metastatic Locally Recurrent Breast Cancer</keyword>
</DOC>